NYSE:KDMNKadmon Stock Price, Forecast & News

$4.44

-0.02 (-0.45 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.27

Now: $4.44▼

$4.52

50-Day Range

$3.94

MA: $4.40▼

$4.84

52-Week Range

$1.63

Now: $4.44▼

$5.50

Volume6.51 million shs

Average Volume2.91 million shs

Market Capitalization$710.53 million

P/E RatioN/A

Dividend YieldN/A

Beta1.48

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Kadmon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Kadmon has a potential upside of 170.3% from its current price of $4.44.
Amount of Analyst Coverage
Kadmon has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Kadmon has received 254 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kadmon has received 235 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kadmon has received 51.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote “Outperform” if you believe KDMN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KDMN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kadmon does not currently pay a dividend.
Dividend Growth
Kadmon does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kadmon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $191,168.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.95% of the stock of Kadmon is held by insiders.
Percentage Held by Institutions
85.64% of the stock of Kadmon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Kadmon are expected to grow in the coming year, from ($0.61) to $0.33 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kadmon is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kadmon is -6.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kadmon has a P/B Ratio of 7.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.15 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:KDMN

Previous Symbol

CUSIPN/A

CIK1557142

Webwww.kadmon.com

Phone833-900-5366

Debt

Debt-to-Equity Ratio0.20

Current Ratio6.42

Quick Ratio6.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.09 million

Price / Sales139.59

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.60 per share

Price / Book7.40

Profitability

EPS (Most Recent Fiscal Year)($0.74)

Net Income$-61,370,000.00

Net Margins-813.33%

Return on Equity-142.79%

Return on Assets-66.34%

Miscellaneous

Employees116

Outstanding Shares160,030,000

Market Cap$710.53 million

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

Kadmon (NYSE:KDMN) Frequently Asked Questions

How has Kadmon's stock been impacted by COVID-19 (Coronavirus)?

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KDMN stock has increased by 27.6% and is now trading at $4.44. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Kadmon?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Kadmon.

How were Kadmon's earnings last quarter?

Kadmon Holdings Inc (NYSE:KDMN) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. The business earned $6.74 million during the quarter, compared to analyst estimates of $0.38 million. Kadmon had a negative return on equity of 142.79% and a negative net margin of 813.33%. View Kadmon's earnings history.

What price target have analysts set for KDMN?

5 brokers have issued twelve-month target prices for Kadmon's shares. Their forecasts range from $7.00 to $25.00. On average, they anticipate Kadmon's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 170.3% from the stock's current price. View analysts' price targets for Kadmon.

Has Kadmon been receiving favorable news coverage?

Media stories about KDMN stock have trended neutral recently, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kadmon earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the next few days. View the latest news aboutKadmon.

Who are some of Kadmon's key competitors?

Some companies that are related to Kadmon include Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX) and Passage Bio (ZNTL). View all competitors.

What other stocks do shareholders of Kadmon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Global Blood Therapeutics (GBT).

Who are Kadmon's key executives?

Kadmon's management team includes the following people:

Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
Mr. Steven Meehan, Exec. VP & CFO (Age 54)
Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
Ms. Cynthia L. Schwalm, Director (Age 59)
Mr. Kyle Carver, Controller & Principal Accounting Officer

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.82%), Vivo Capital LLC (7.84%), BlackRock Inc. (7.53%), State Street Corp (2.33%), Geode Capital Management LLC (1.41%) and Invesco Ltd. (1.12%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

Which major investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Invesco Ltd., Nuveen Asset Management LLC, Ghost Tree Capital LLC, Two Sigma Investments LP, Soleus Capital Management L.P., Telemetry Investments L.L.C., and Acadian Asset Management LLC. View insider buying and selling activity for Kadmon.

Which major investors are buying Kadmon stock?

KDMN stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, Perceptive Advisors LLC, Healthcare of Ontario Pension Plan Trust Fund, and Two Sigma Advisers LP. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $4.44.

How big of a company is Kadmon?

Kadmon has a market capitalization of $710.53 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is www.kadmon.com.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff